A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)

Stopped The study met the protocol defined stopping boundary for Day 60 mortality when comparing mortality between the T-Guard and ruxolitinib arms

Conditions

• Steroid-Refractory Acute Graft Versus Host Disease

Interventions

• DRUG: T-Guard
• DRUG: Ruxolitinib

Sponsor

Xenikos

Collaborators

• [object Object]
• [object Object]
• [object Object]
• [object Object]